A Phase II Study of Docetaxel, Cisplatin and 5- Fluorouracil (TPF) In Patients with Locally Advanced Head and Neck Carcinomas


M Ansari 1 , S Omidvari 1 , A Mosalaei 1 , N Ahmadloo 1 , MA Mosleh-Shirazi 1 , M Mohammadianpanah 2 , *

1 Department of Radiation Oncology, Nemazee Hospital, Shiraz University of Medical Sciences, Fars, Iran

2 Associate Professor of Radiation Oncology, Nemazee Hospital,Shiraz University of Medical Sciences, [email protected], Fars, Iran

How to Cite: Ansari M, Omidvari S, Mosalaei A, Ahmadloo N, Mosleh-Shirazi M, et al. A Phase II Study of Docetaxel, Cisplatin and 5- Fluorouracil (TPF) In Patients with Locally Advanced Head and Neck Carcinomas, Iran Red Crescent Med J. Online ahead of Print ; 13(3):187-191.


Iranian Red Crescent Medical Journal: 13 (3); 187-191
Article Type: Research Article
Received: July 10, 2010
Accepted: September 27, 2010




Introduction: The combination of cisplatin and 5-fluorouracil (PF) is currently considered a standard and effective regimen for the treatment of advanced head and neck carcinomas. The aim of this study was to evaluate the efficacy and safety of docetaxel, cisplatin and 5-fluorouracil (TPF) in patients with unresectable head and neck carcinomas.

Methods: Forty-six patients with previously untreated non-metastatic stage IV head and neck carcinomas were enrolled. All patients received three cycles of induction chemotherapy with docetaxel (75 mg/m2), cisplatin (40 mg/m2) (days 1-2), and 5-FU (500 mg/m2, days 1-3), repeated every 21 days. Following induction chemotherapy, all patients underwent concurrent chemoradiotherapy using weekly cisplatin (30 mg/m2) and a median total dose of 70 Gy was delivered.Clinical response rate and toxicity were the primary and secondary end-points of the study.

Results: There were 31 men and 15 women. All patients had non-metastatic stage IV (T2-3N2-3 or T4N0-3) of disease. Overall and complete response rates were 74% and 24% respectively. Advanced T4 classification was associated with poorer response rate (p value=0.042). The major (grade 3-4) treatment-related toxicities were myelosuppression (78%), anorexia (13%), diarrhea (7%), emesis (11%) and stomatitis/pharyngitis (24%).  

Conclusion: In comparison with the data of historical published trials of the PF regimen, the TPF regimen was more effective. However, the TPF regimen appears to be associated with a higher incidence of major toxicities. Therefore, our limited findings support the TPF regimen as an alternative chemotherapeutic regimen for advanced head and neck carcinomas.


Docetaxel Cisplatin 5-Fluorouracil Chemotherapy Head and neck Carcinoma

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF